Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 223

1.

Achieving Clinical Remission for Patients With Rheumatoid Arthritis.

Aletaha D, Smolen JS.

JAMA. 2019 Feb 5;321(5):457-458. doi: 10.1001/jama.2018.21249. No abstract available.

PMID:
30721278
2.

Workforce requirements in rheumatology: a systematic literature review informing the development of a workforce prediction risk of bias tool and the EULAR points to consider.

Unger J, Putrik P, Buttgereit F, Aletaha D, Bianchi G, Bijlsma JWJ, Boonen A, Cikes N, Dias JM, Falzon L, Finckh A, Gossec L, Kvien TK, Matteson EL, Sivera F, Stamm TA, Szekanecz Z, Wiek D, Zink A, Dejaco C, Ramiro S.

RMD Open. 2018 Dec 5;4(2):e000756. doi: 10.1136/rmdopen-2018-000756. eCollection 2018.

3.

EULAR 'points to consider' for the conduction of workforce requirement studies in rheumatology.

Dejaco C, Putrik P, Unger J, Aletaha D, Bianchi G, Bijlsma JW, Boonen A, Cikes N, Finckh A, Gossec L, Kvien TK, Madruga Dias J, Matteson EL, Sivera F, Stamm TA, Szekanecz Z, Wiek D, Zink A, Ramiro S, Buttgereit F.

RMD Open. 2018 Dec 5;4(2):e000780. doi: 10.1136/rmdopen-2018-000780. eCollection 2018.

4.

Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity.

Landewé R, Ritchlin CT, Aletaha D, Zhang Y, Ganz F, Hojnik M, Coates LC.

Rheumatology (Oxford). 2019 Jan 3. doi: 10.1093/rheumatology/key417. [Epub ahead of print]

PMID:
30608620
5.

Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study.

Norvang V, Sexton J, Kristianslund EK, Olsen IC, Uhlig T, Bakland G, Krøll F, Rødevand E, Wierød A, Kvien TK, Smolen JS, Aletaha D, Haavardsholm EA.

RMD Open. 2018 Oct 26;4(2):e000773. doi: 10.1136/rmdopen-2018-000773. eCollection 2018.

6.

Diagnosis and Management of Rheumatoid Arthritis: A Review.

Aletaha D, Smolen JS.

JAMA. 2018 Oct 2;320(13):1360-1372. doi: 10.1001/jama.2018.13103. Review.

PMID:
30285183
7.

Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified Disease Activity index for PSoriatic Arthritis (DAPSA) based on 28 joints?

Michelsen B, Sexton J, Smolen JS, Aletaha D, Krogh NS, van der Heijde D, Kvien TK, Hetland ML.

Ann Rheum Dis. 2018 Dec;77(12):1736-1741. doi: 10.1136/annrheumdis-2018-213463. Epub 2018 Sep 20.

PMID:
30237203
8.

Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey.

Roodenrijs NMT, de Hair MJH, van der Goes MC, Jacobs JWG, Welsing PMJ, van der Heijde D, Aletaha D, Dougados M, Hyrich KL, McInnes IB, Mueller-Ladner U, Senolt L, Szekanecz Z, van Laar JM, Nagy G; whole EULAR Task Force on development of EULAR recommendations for the comprehensive management of difficult-to-treat rheumatoid arthritis.

Ann Rheum Dis. 2018 Dec;77(12):1705-1709. doi: 10.1136/annrheumdis-2018-213687. Epub 2018 Sep 7.

PMID:
30194273
9.

Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial.

Stamm TA, Machold KP, Aletaha D, Alasti F, Lipsky P, Pisetsky D, Landewe R, van der Heijde D, Sepriano A, Aringer M, Boumpas D, Burmester G, Cutolo M, Ebner W, Graninger W, Huizinga T, Schett G, Schulze-Koops H, Tak PP, Martin-Mola E, Breedveld F, Smolen J.

Arthritis Res Ther. 2018 Aug 9;20(1):174. doi: 10.1186/s13075-018-1667-z.

10.

Predictors for influenza vaccine acceptance among patients with inflammatory rheumatic diseases.

Harrison N, Poeppl W, Miksch M, Machold K, Kiener H, Aletaha D, Smolen JS, Forstner C, Burgmann H, Lagler H.

Vaccine. 2018 Aug 6;36(32 Pt B):4875-4879. doi: 10.1016/j.vaccine.2018.06.065. Epub 2018 Jul 3.

PMID:
29980390
11.

Are we failing patients in our assessment of treatment failure?

Nikiphorou E, Aletaha D, Bukhari M.

Rheumatology (Oxford). 2018 Apr 19. doi: 10.1093/rheumatology/key107. [Epub ahead of print] No abstract available.

PMID:
29897585
12.

To DAPSA or not to DAPSA? That is not the question.

Schoels MM, Smolen JS, Aletaha D.

Ann Rheum Dis. 2018 May 5. pii: annrheumdis-2018-213548. doi: 10.1136/annrheumdis-2018-213548. [Epub ahead of print] No abstract available.

PMID:
29730635
13.

Missing pebble in the mosaic of rheumatic diseases and mental health: younger does not always mean happier.

Alunno A, Studenic P, Wiek D, Balážová P, Aletaha D.

Ann Rheum Dis. 2018 Apr 28. pii: annrheumdis-2018-213611. doi: 10.1136/annrheumdis-2018-213611. [Epub ahead of print] No abstract available.

PMID:
29705744
14.

Early response to therapy predicts 6-month and 1-year disease activity outcomes in psoriatic arthritis patients.

Schoels MM, Landesmann U, Alasti F, Baker D, Smolen JS, Aletaha D.

Rheumatology (Oxford). 2018 Jun 1;57(6):969-976. doi: 10.1093/rheumatology/key004.

PMID:
29481661
15.

Tofacitinib for Psoriatic Arthritis.

Aletaha D, Kerschbaumer A, Smolen JS.

N Engl J Med. 2018 Feb 22;378(8):775. doi: 10.1056/NEJMc1715189. No abstract available.

PMID:
29469555
16.

Rheumatoid arthritis.

Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, Kavanaugh A, McInnes IB, Solomon DH, Strand V, Yamamoto K.

Nat Rev Dis Primers. 2018 Feb 8;4:18001. doi: 10.1038/nrdp.2018.1. Review.

PMID:
29417936
17.

The effects of structural damage on functional disability in psoriatic arthritis.

Kerschbaumer A, Baker D, Smolen JS, Aletaha D.

Ann Rheum Dis. 2017 Dec;76(12):2038-2045. doi: 10.1136/annrheumdis-2017-211433. Epub 2017 Aug 23.

PMID:
28835465
18.

Clinical and economic analysis of outcomes of dose tapering or withdrawal of tumor necrosis factor-α inhibitors upon achieving stable disease activity in rheumatoid arthritis patients.

Aletaha D, Snedecor SJ, Ektare V, Xue M, Bao Y, Garg V.

Clinicoecon Outcomes Res. 2017 Jul 28;9:451-458. doi: 10.2147/CEOR.S136327. eCollection 2017.

19.

Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force.

Smolen JS, Schöls M, Braun J, Dougados M, FitzGerald O, Gladman DD, Kavanaugh A, Landewé R, Mease P, Sieper J, Stamm T, Wit M, Aletaha D, Baraliakos X, Betteridge N, Bosch FVD, Coates LC, Emery P, Gensler LS, Gossec L, Helliwell P, Jongkees M, Kvien TK, Inman RD, McInnes IB, Maccarone M, Machado PM, Molto A, Ogdie A, Poddubnyy D, Ritchlin C, Rudwaleit M, Tanew A, Thio B, Veale D, Vlam K, van der Heijde D.

Ann Rheum Dis. 2018 Jan;77(1):3-17. doi: 10.1136/annrheumdis-2017-211734. Epub 2017 Jul 6. Erratum in: Ann Rheum Dis. 2018 Mar;77(3):472.

20.

Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition.

Schoels M, Alasti F, Smolen JS, Aletaha D.

Arthritis Res Ther. 2017 Jul 4;19(1):155. doi: 10.1186/s13075-017-1346-5.

Supplemental Content

Loading ...
Support Center